trial

Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

NCTId NCT06328140
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Withdrawn
Enrollment 0 (actual)
Sponsored by George West Mental Health Foundation d/b/a Skyland Trail
Primary completion 2025-01-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Withdrawn
Enrollment
0 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2024-04-15
Primary completion
2025-01-22
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
LurasidoneFDA Approved antidepressant treatment

Sponsors

George West Mental Health Foundation d/b/a Skyland TrailLead Sponsor
Sumitomo Pharmaceuticals AmericaCollaborator

Investigators

1
Ben W Hunter, MDPrincipal Investigator

Sites

1 total
Atlanta, United States

Facts & assertions

4 sourced
Enrollment
0
Phase
NA
Primary Completion Date
2025-01-22
Status
WITHDRAWN
relationships
The graph out of here
drug
Lurasidone
drug
FDA Approved antidepressant treatment
drug
lead_sponsor
George West Mental Health Foundation d/b/a Skyland Trail
company
collaborator
Sumitomo Pharmaceuticals America
company
indication
Bipolar Disorder
indication
Major Depressive Disorder
indication
Psychosis
indication
investigator
Ben W Hunter, MD
person